TB-500 Side Effects: Complete Safety Profile, the Cancer-Risk Question & Real-World Reports

✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

TB-500 is the second-most-discussed recovery peptide on the internet — and like its cousin BPC-157, it sits in a curious limbo where most articles either dismiss the safety concerns (“no toxicity ever reported!”) or amplify them past what the literature supports (“TB-500 causes metastasis!”). Neither is honest. The actual picture is more interesting and more useful.

This guide does the harder thing. We walk through what controlled animal studies actually report, what real human users describe, what the theoretical concerns are (angiogenesis, cell migration, the metastasis-promotion question that does have published mechanistic backing), and the practical risk factors — impurity, overdosing, untested blends, drug interactions — that turn a generally well-tolerated compound into a problem.

How TB-500 Works (the 60-second version)

“TB-500” is the colloquial name for synthetic thymosin-β4 (Tβ4), a 43-amino-acid peptide naturally present in nearly every human cell. Some commercial vials contain the full 43-amino-acid sequence; others contain only the active 7-amino-acid fragment (LKKTETQ), which is the region thought to drive most of the cell-migration and tissue-repair effects. The two are not pharmacokinetically identical, which matters for dosing and for interpreting side-effect reports.

The proposed mechanisms include actin sequestration (the peptide binds G-actin and modulates cytoskeletal reorganisation), promotion of cell migration in fibroblasts, endothelial cells and stem-cell populations, upregulation of angiogenesis through VEGF and related signalling, and broad anti-inflammatory effects via downregulation of pro-inflammatory cytokines including IL-8 and MIP-1β.

Those mechanisms matter for understanding the side-effect profile. A peptide that pushes cells to migrate and tissue to vascularise will not have a “completely clean” risk profile by definition — the question is where the trade-off sits in real human use. For the full mechanism breakdown, dose ranges, and use-case decision tree, see our complete TB-500 guide.

TB-500 Side Effects: What Animal Studies Actually Report

The published research on thymosin-β4 spans more than three decades, originating from work by Allan Goldstein at George Washington University and a wider network of groups studying tissue regeneration. Rodent and large-animal studies have administered TB-500 across cardiac ischaemia, corneal wound, dermal wound, EAE (multiple-sclerosis model), and spinal-cord injury protocols, at doses ranging from 100 µg/kg to 12 mg/kg, without producing a consistent dose-limiting toxicity. Lethality has not been established within the doses tested. Organ histopathology in long-duration studies has shown no consistent structural changes attributable to the peptide.

That said, the same caveats that apply to BPC-157 apply here: “no signal in published rodent work” is not the same as “safe for humans long-term.” Importantly, a handful of cell-line and animal-tumour studies have explored Tβ4’s role in cancer biology specifically, and the picture there is mixed — protective in some models, neutral in others, growth-promoting in a few. The honest summary is that the non-cancer acute toxicity profile in animals looks clean, and the chronic and cancer-context profile in humans is essentially unstudied.

Human-Reported Side Effects: The Honest List

Since TB-500 is not approved by any major regulatory agency for general human therapeutic use, there is no formal pharmacovigilance database. What we have is forum reports, clinician case notes from research-context use, the small set of phase I/II trial adverse-event summaries, and a few self-reported survey datasets. Pooling those informal sources produces a recurring shortlist.

Injection-site reactions

The most commonly reported side effect. Subcutaneous TB-500 can cause mild redness, a small raised bump, or transient stinging at the injection site. This typically settles within an hour and resolves within 24 hours. Rotating injection sites and using a 30G or 31G insulin needle reduces incidence. Larger volumes (above ~1 mL) increase the rate noticeably — split a high-dose injection into two sites rather than one.

Lethargy and “head fog”

More frequently reported with TB-500 than with BPC-157, and a recurring theme in forum reports. Users often describe a mild fatigue or mental cloudiness in the first 5–10 days of a loading phase (typically dosed 2–5 mg per week split into two or three injections). Mechanism is unclear — likely related to TB-500’s effects on inflammatory signalling and possibly to early shifts in tissue remodelling. Almost always self-limiting; if it persists past two weeks, reduce the loading dose by half.

Mild flu-like symptoms during loading

A minority of users report mild muscle aches, low-grade temperature elevation, or general malaise in the first week. These typically resolve as the loading phase ends and the dose drops to maintenance levels (often 2 mg per week or less).

Headaches

Reported less frequently than with BPC-157, but well-documented. Likely related to vasodilatory and nitric-oxide effects of the peptide. Adequate hydration and dose reduction usually help.

Vivid dreams and sleep changes

A recurring report from longer-cycle users — vivid or unusual dreams in the first 2–3 weeks. Most resolve with continued use. A small minority report mild insomnia or sleep-onset delay; shifting the injection time to the morning rather than evening tends to help.

Transient hypoglycaemia

Rare but worth flagging. Some users with metabolic sensitivity or those running TB-500 alongside other GH-axis peptides report mild low-blood-sugar symptoms (lightheadedness, hunger, mild tremor) 30–90 minutes post-injection. Snack-and-monitor is the practical fix; if it recurs, reduce the dose.

Localised “warmth” or itching after injection

Cosmetically benign but worth noting. A small subset of users describe a warmth or mild itching radiating from the injection site for 15–60 minutes. Almost always self-limiting and not associated with allergic reaction; antihistamines are not needed unless a true urticarial response develops.

The Real Theoretical Concerns

1. Angiogenesis, cell migration, and the metastasis question

This is the most important and most often-mishandled topic in TB-500 discussion, and it deserves to be stated plainly. Two of thymosin-β4’s mechanisms — promotion of angiogenesis and promotion of cell migration — are also two of the mechanisms by which solid tumours grow and metastasise. There is a published mechanistic literature linking Tβ4 over-expression to metastatic potential in colorectal, hepatocellular, and gastric cancer cell lines, and to worse prognosis in some tumour-tissue immunohistochemistry studies.

That is not the same as evidence that TB-500 causes cancer in humans. There is no published study that has shown that. What it does mean is that the mechanistic case for caution is stronger than it is for BPC-157, because both the angiogenic component and the cell-migration component of metastasis are TB-500-relevant pathways. The practical implication is conservative: TB-500 is probably not the right compound for anyone with a known cancer diagnosis, active malignancy, or recent history of an angiogenesis- or migration-driven cancer (some breast, colorectal, hepatocellular, and gastric cancers in particular). A baseline cancer screen appropriate to age and sex before starting longer cycles is a reasonable default.

2. Long-term human safety data does not exist

TB-500 has been in informal recreational use since roughly 2009–2010, with the published human-trial population sitting in the low hundreds at most. That is too short and too small to detect rare adverse events — the kind that show up at 1-in-10,000 or longer time horizons. Antibody formation, immunogenicity, latent autoimmune triggers, and rare endocrine effects could exist and not yet have been seen.

The most honest position: TB-500 looks generally safe acutely based on what we have, and what we have is not enough to make strong long-term claims. Plan cycles accordingly — most reasonable protocols use 4–8 week loading-plus-maintenance phases with off-periods of similar length, not continuous indefinite use. See our peptide cycling protocols guide for the framework.

Risk Factors That Amplify Side Effects (the part most articles skip)

Most “I had a bad reaction to TB-500” stories online turn out, on closer inspection, to be one of the following four problems. Address these and the side-effect rate drops sharply.

Impurity from an unverified supplier

TB-500 is synthesised via solid-phase peptide synthesis. The final product is the target peptide plus impurities: truncation products (shorter sequences that did not fully synthesise), deletion products, deamidation products, and residual solvents. A reputable supplier publishes a Certificate of Analysis (COA) showing HPLC purity above 98% and mass spectrometry confirming sequence identity. An unverified supplier may ship product at 70–85% purity — and the impurity profile is where a significant share of the “TB-500 side effects” reported online actually live.

If your peptide came without a COA — or with one that does not list HPLC area-percent purity and mass-spec confirmation — treat any side effect you experience as a supplier-quality issue first and a peptide issue second. Our guide to reading a peptide COA walks through what to demand.

Overdosing the loading phase

Typical TB-500 research protocols use a loading phase of 4–8 mg per week (split into two or three subcutaneous injections) for the first 4–6 weeks, then drop to a maintenance dose of around 2 mg per week. Some forum protocols recommend 10–20 mg per week “for faster results.” Above the standard loading range, the dose-response curve flattens in most rodent models — the additional dose does not buy more healing, but it does buy a higher impurity load and a markedly higher probability of the lethargy/head-fog cluster of effects. Start in the standard range and adjust based on response.

Untested blends

Pre-mixed peptide blends (most commonly BPC-157 + TB-500 in a single vial) are convenient but introduce two new risks: you cannot independently verify the purity or concentration of each component, and any side effect you experience is ambiguous — was it the TB-500, the BPC-157, or an impurity from one of them? For investigation cycles where you want to isolate TB-500’s effect specifically, use a single-component vial. Blends are reasonable once you have established tolerance to each component separately. See our peptide blends explained guide for stack-design context.

Drug interactions

TB-500 has not been formally studied for pharmacokinetic interactions, but several theoretical concerns are worth flagging. Anticoagulants warrant attention because of the vasodilatory and potential haemorheological effects of the peptide. Immunomodulators (especially in autoimmune patients) and chemotherapy agents all warrant a conservative pause-and-discuss approach rather than co-administration. Concurrent use with growth-hormone secretagogues amplifies the metabolic shift in the first 1–2 weeks and increases the rate of mild hypoglycaemia reports.

When TB-500 Is Probably NOT for You

• Active cancer or recent cancer history. The angiogenic and cell-migration mechanisms are both relevant — until human oncology data exists, this is a real precaution, not theatre.
• Pregnancy or breastfeeding. No human data. Default to no.
• Active autoimmune disease. TB-500 modulates inflammatory and migratory signalling. The direction of effect in an active flare is not well characterised.
• Children and adolescents. No paediatric data. Growth-axis and tissue-remodelling effects are theoretically more consequential during development.
• WADA-tested athletes. TB-500 falls under S2 (peptide hormones, growth factors) on the WADA prohibited list. Sanctions apply year-round, in and out of competition, regardless of dose.
• Anyone using an unverified-source vial. If you cannot see a COA, the side-effect profile you will experience is the impurity profile, not the TB-500 profile.

How to Lower Your Side-Effect Risk

If you have decided TB-500 fits your situation and you have a research context for using it, the practical risk-management checklist is short.

1. Reconstitute correctly. Bacteriostatic water, not plain sterile water — the benzyl alcohol preservative keeps the vial usable for 28+ days after reconstitution. See our reconstitution math guide for the syringe-mark conversions.
2. Start at the low end of the loading dose. 2 mg per week split into two 1 mg injections, for the first week. Most users tolerate this with no adverse effects. If you feel fine, you can move up to 4 mg per week in weeks two through six.
3. Rotate injection sites — abdomen quadrants are the standard rotation, with the lateral thighs as an alternate. Use a 30G or 31G insulin needle.
4. Plan cycles, do not run continuously. A typical cycle is 4–6 weeks loading + 2–4 weeks maintenance, followed by an off-period of similar length. There is no evidence that continuous use is safer than cycling.
5. Demand a COA. HPLC purity ≥98%, mass-spec confirmation of the sequence, identified manufacturer, and a lot number on the vial.
6. Log what you feel. Keep a brief log of dose, injection site, and any sensations within 4 hours and the following 24 hours. This separates real side effects from noise and lets you spot a pattern early.

TB-500 Side Effects vs Other Recovery Peptides

Context helps here. TB-500 is not the only research peptide with a side-effect profile to weigh, and a comparison row makes the picture sharper.

The takeaway: TB-500 and BPC-157 share the angiogenesis concern because that mechanism is shared, and TB-500 carries an additional cell-migration component that is mechanistically relevant to metastasis. Neither peptide has a “perfectly clean” risk profile, because every active compound has a mechanism that does something. The job is to match the compound, dose, and cycle length to the use case and the user’s risk profile honestly.

WADA and Regulatory Status

TB-500 is prohibited at all times — in and out of competition — under WADA’s S2 category (“peptide hormones, growth factors, related substances and mimetics”). S2 is distinct from BPC-157’s S0 listing: S2 covers compounds with a clear hormone- or growth-factor-like mechanism, while S0 catches any substance not approved by a national regulator for human therapeutic use. The practical consequence is identical: a positive test triggers sanctions regardless of dose. Tested athletes should avoid TB-500 entirely. Recreational use by non-tested individuals does not carry WADA consequences, but workplace or insurance considerations may still apply.

From a national regulator standpoint, TB-500 is not approved as a drug by the FDA, EMA, MHRA, or Health Canada. The FDA placed thymosin-β4 on the Section 503A bulk substances “Category 2” list in 2023, restricting compounding pharmacies in the US from preparing it for patients. Other regulators have not issued the same restriction. The peptide remains globally available as a research compound through suppliers that publish a COA and ship with appropriate labelling.

Frequently Asked Questions

What are the most common side effects of TB-500?

Mild injection-site reactions (redness, stinging, a small bump) are the most common, followed by lethargy or mental “head fog” during the loading phase, occasional flu-like symptoms in the first week, mild headaches, and vivid dreams in some longer-cycle users. Most effects resolve within 24–72 hours and respond to a dose reduction. Severe effects are rare in the published animal data and informally rare in human use.

Does TB-500 cause cancer?

No published study has shown TB-500 causing cancer. The theoretical concern is stronger than for BPC-157 because thymosin-β4 has a documented role in both angiogenesis and cell migration — the two processes underlying tumour growth and metastasis — and there is published mechanistic literature linking Tβ4 over-expression to metastatic potential in several cancer cell lines. Translation: TB-500 is unlikely to cause cancer, but the mechanistic case for accelerating an already-existing undiagnosed tumour is more substantive than for BPC-157. Anyone with cancer history, recent cancer treatment, or strong family history of angiogenesis- or migration-driven cancers should discuss with a clinician before use.

Is TB-500 safe long-term?

The honest answer: nobody knows. The published human-trial population is in the low hundreds and trial durations have been short. That is too small and too short a window to detect rare or delayed adverse events. Animal studies up to several months in duration are reassuring, but they do not substitute for human longitudinal data. The prudent default is to cycle (4–6 weeks loading, 2–4 weeks maintenance, then equal time off) rather than run continuously.

Why does TB-500 make me tired during the loading phase?

Mild fatigue or mental cloudiness in the first 5–10 days of loading is the most-reported “systemic” side effect of TB-500. Likely related to early shifts in tissue remodelling and inflammatory signalling. Almost always self-limiting. If lethargy persists past two weeks or affects daily function, reduce the loading dose by half and allow another week to assess.

Is TB-500 banned by WADA?

Yes. TB-500 falls under the S2 category (peptide hormones, growth factors and related substances) on the WADA prohibited list. It is banned in and out of competition. A positive test triggers sanctions regardless of dose. Tested athletes should not use it.

What happens if you take too much TB-500?

Lethality has not been established in rodent studies, even at very high doses. Practical overdose symptoms in humans are usually amplified versions of the normal side effects: stronger injection-site reactions, more pronounced lethargy or head fog, occasional flu-like malaise, headaches. Stop dosing, hydrate, and let the peptide clear. The half-life is short — effects typically subside within 24–48 hours.

Can you take TB-500 with BPC-157?

Combining them is common in informal protocols and is the basis of several pre-mixed blend products. Mechanistically the two are complementary — TB-500 promotes cell migration and broad tissue remodelling, BPC-157 promotes localised vascular healing and gut-axis effects. The trade-off is that blends make side-effect attribution ambiguous; if you experience a problem you will not know which component to adjust. For an investigation cycle, single-component vials are cleaner. See our BPC-157 vs TB-500 comparison for full stack-design context.

Does TB-500 cause hair loss or hair growth?

Anecdotal reports run in both directions. The biological basis for either is weak — TB-500 is not a known modulator of the androgen-driven follicular miniaturisation pathway, and reports of growth or shedding likely reflect the broader cell-migration and inflammatory-modulation effects acting on follicular tissue heterogeneously. Treat both directions as low-confidence anecdote.

How long should a TB-500 cycle last?

Typical research protocols use a 4–6 week loading phase at 4–8 mg per week, followed by a 2–4 week maintenance phase at around 2 mg per week, then a 4–6 week off-period. Some acute-injury protocols compress this to a 4-week loading cycle only. There is no published evidence that continuous use is safer than cycling, and cycling is the more conservative default given the absence of long-term human data.

Should I get bloodwork before starting TB-500?

For any longer cycle (more than 4 weeks) or when stacking with other peptides, baseline bloodwork is reasonable: a complete blood count, comprehensive metabolic panel, and any cancer screening appropriate to your age and sex. Repeat the same panel after the cycle. This gives you a clean comparator if anything changes and is the responsible default for any extended peptide protocol.

How do I know if my TB-500 side effects are from the peptide or the supplier?

The cleanest test is the COA. If your vial came with a Certificate of Analysis showing HPLC purity ≥98% and mass-spec sequence confirmation, side effects are more likely peptide-related and will respond to dose adjustment. If your vial came without verification, the impurity load is unknown and you should treat any adverse reaction as a sourcing problem first. Verified suppliers should also publish lot numbers and manufacture dates.

The Honest Summary

TB-500 has a clean acute toxicity profile in animal research, a mostly mild and self-limiting side-effect profile in human users (with lethargy and head fog during the loading phase being the most distinctive feature), and a small set of theoretical long-term concerns. The cancer-and-metastasis question is more substantive for TB-500 than for BPC-157 because thymosin-β4 has documented mechanistic relevance to both angiogenesis and cell migration — the two pathways at the heart of tumour growth and metastasis. There is no published evidence of human harm, but the mechanistic case for caution is real.

Most reported “side effects” trace back to one of four practical issues — impurity, overdose, untested blends, or drug interactions — and addressing those four reduces the real-world side-effect rate substantially. The compound is not for everyone. It is not for anyone with an active cancer history, anyone pregnant or breastfeeding, anyone in a WADA-tested sport, and anyone who cannot get a COA-verified source. For the population that fits the use case, treats it as research-grade, cycles responsibly, and sources carefully, the risk profile remains favourable enough that TB-500 is a reasonable second choice (after BPC-157) for tissue-recovery research.

For deeper protocol detail, see our complete TB-500 guide and the sister BPC-157 side effects guide for the mechanistic-cousin comparison. For stack design, the BPC-157 vs TB-500 comparison is the right landing page. You can browse the full COA-verified research-peptide catalogue or jump directly to the single-component TB-500 vial or the pre-mixed BPC-157 + TB-500 blend if you have already established single-component tolerance.

Every order is covered by our Reshipment Assurance Policy: if your parcel does not arrive within 20 business days of dispatch (EMS or ITPS), we send a replacement at no extra cost.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.